Microbial agents including periodontal pathogens have recently appeared as important actors in Alzheimer's disease (AD) pathology. 1 key finding →
Evidence: high
Full summary, score breakdown and related studies → Original source
Research
27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
Recent Medicare claims perform reasonably well in identifying dementia; however, there are consistent differences in cases of dementia identified through claims than in rigorous cohort evaluations. 5 key findings →
Participants: 54 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Mean BBC in FY 2014 was 0.32; mean total cost in FY 2015 was $35 425. 4 key findings →
Participants: 102 Evidence: low
Full summary, score breakdown and related studies → Original source
The costs of dementia fall on families, highlighting limited policy and work supports. 2 key findings →
Design: modelling Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
BackgroundSeveral monoclonal antibodies designed to slow cognitive and functional decline in individuals with early Alzheimer's disease (AD) have been recently approved. 5 key findings →
Design: systematic-review Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
48/100
This study projects that the total cost of caring for Americans with Alzheimer's and related dementias will grow enormously over the coming decades, driven by an aging population. 4 key findings →
Design: modelling Evidence: moderate
Full summary, score breakdown and related studies → Original source
Before donanemab was approved, researchers built a computer model simulating lifetime outcomes for Alzheimer's patients to estimate whether aducanumab and donanemab were reasonably priced for the health benefit they provide. 4 key findings →
Design: modelling Evidence: moderate
Full summary, score breakdown and related studies → Original source
The future price of lecanemab in European countries is unknown. 2 key findings →
Design: modelling Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
A collaborative dementia care program demonstrated significant financial benefit in a managed Medicare population. 4 key findings →
Design: cohort Participants: 242 Evidence: early
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Our review supports that biofluid biomarker testing could be cost-effective to diagnose AD. 2 key findings →
Design: systematic-review Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Parkinson's disease (PD), following Alzheimer's disease, is the second-most common neurodegenerative disorder in the United States. 5 key findings →
Participants: 630,000 Evidence: low
Full summary, score breakdown and related studies → Original source
Just under a half of the expected numbers of patients with dementia are recognised in GP dementia registers. 4 key findings →
Participants: 351 Evidence: low
Full summary, score breakdown and related studies → Original source
Although persons with dementia are frequently hospitalized, relatively little is known about the health profile, patterns of health care use, and mortality rates for patients with dementia who access care in the emergency department (ED). 4 key findings →
Participants: 10,354 Evidence: low
Full summary, score breakdown and related studies → Original source
We identified a cohort of 3619 incident dementia cases, 38.9% were male, and 66.9% were non-Hispanic White. 5 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
This cross-sectional study examines upper bound and lower bound annualized Medicare costs for administering aducanumab to beneficiaries with the approved indications of mild cognitive impairment or mild dementia. 1 key finding →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source
The average cost per enrollee per month was $110, or $1,320 per annum. 5 key findings →
Participants: 360 Evidence: low
Full summary, score breakdown and related studies → Original source
In both databases, total healthcare resource utilization and costs increased with number of core features. 4 key findings →
Participants: 536 Evidence: low
Full summary, score breakdown and related studies → Original source
On average, ADRD diagnosis was not significantly associated with excess Medicare payments over the last 5 years of life. 5 key findings →
Participants: 4,899 Evidence: low
Full summary, score breakdown and related studies → Original source
Most PWD (67%) met criteria for another manifestation of serious illness (24% advanced medical condition, 44% ADL impairment). 5 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source
This global study estimated how much dementia costs the world, combining formal healthcare spending with the value of unpaid family caregiving across 204 countries. 4 key findings →
Design: modelling Evidence: moderate
Full summary, score breakdown and related studies → Original source
Despite the differences in partner's dementia status, we found no significant difference in the 5-year cumulative Medicare expenditures between SPWD and SPWND. 5 key findings →
Design: cohort Evidence: early
Full summary, score breakdown and related studies → Original source Free full text
BackgroundThere are 5.5 million people living with dementia in the United States (US), with the cost of unpaid care making up a significant portion of the care costs. 2 key findings →
Design: modelling Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Current annual replacement cost of unpaid family care is between $96 and $182 billion, 44% of which is accounted for by dementia caregiving. 1 key finding →
Design: modelling Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Recovery rates are low, even among those with higher levels of pre-fracture functional status, and are worse for patients who are older, cognitively impaired, and who have multiple comorbidities. 3 key findings →
Participants: 733 Evidence: low
Full summary, score breakdown and related studies → Original source
The Inflation Reduction Act Medicare Part D benefit redesign will reduce OOP drug spending for beneficiaries with dementia, resulting in potentially marked savings not only for low-income beneficiaries and beneficiaries with a high comorbidity burden but also for higher-income beneficiaries. 1 key finding →
Design: modelling Participants: 1,677 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →